Please login to the form below

Not currently logged in
Email:
Password:

Larry Bell joins Dutch biopharma Prosensa

Takes up role as head of global regulatory affairs

Prosena Larry BellDutch biopharmaceutical company Prosensa Therapeutics has appointed Larry Bell as head of global regulatory affairs.

He joins the Leiden-based company with more than 18 years of regulatory affairs experience gained at companies that include Merck, Bristol-Myers Squibb, Aventis and Amgen.

Prior to setting up his own consultancy, his most recent role was as vice president and global head of regulatory affairs at GE Healthcare

For his new role at Prosensa, which focuses on RNA-modulating therapeutics for rare diseases with high unmet need, Bell will be based in the US and oversee the company's global regulatory activities.

Bell said: “This is a key time to be joining the Prosensa team. As the orphan drugs space grows in size and scope, there are many regulatory considerations that need to be addressed in order for new drugs to reach the patients that need them.

“I look forward to helping progress Prosensa's cutting-edge therapies through the regulatory process.”

18th February 2013

From: Research

Share

Tags

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

The 17th World Congress on Controversies in Neurology
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
Tuberculosis – why it remains a major global public health challenge
Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...